Annika Åstrand

机构：AstraZeneca (Netherlands), AstraZeneca (Singapore), AstraZeneca (Finland) · ORCID：0000-0002-4231-6682

发表论文 44 篇 · 总被引 814 次 · h-index 15

代表论文

• Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease‐associated psychological morbidity (2019 · British Journal of Dermatology · 被引 93)
• Alopecia areata patients show deficiency of FOXP3+CD39+ T regulatory cells and clonotypic restriction of Treg TCRβ-chain, which highlights the immunopathological aspect of the disease (2019 · PLoS ONE · 被引 50)
• Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism (2023 · Journal of Medicinal Chemistry · 被引 29)
• Redox regulation of PTPN22 affects the severity of T-cell-dependent autoimmune inflammation (2022 · eLife · 被引 27)
• Effect of COVID-19 on Bronchiectasis Exacerbation Rates: A Retrospective U.S. Insurance Claims Study (2023 · Annals of the American Thoracic Society · 被引 15)
• Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia (2024 · Respiratory Medicine · 被引 14)